{"id":464500,"date":"2021-03-24T14:37:47","date_gmt":"2021-03-24T18:37:47","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=464500"},"modified":"2021-03-24T14:37:47","modified_gmt":"2021-03-24T18:37:47","slug":"hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/","title":{"rendered":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys"},"content":{"rendered":"
\n

SAN FRANCISCO, March 24, 2021 (GLOBE NEWSWIRE) — Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) <\/strong>investors with significant losses to submit your losses now<\/a>. The firm is investigating possible securities law violations and certain investors may have valuable claims.<\/p>\n

\n Visit:<\/strong>
\n www.hbsslaw.com\/investor-fraud\/ACAD<\/a>
\n
\n Contact An Attorney Now:<\/strong>
\n ACAD@hbsslaw.com<\/a>
\n
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 844-916-0895<\/strong><\/p>\n

\n Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Investigation: <\/strong>\n <\/p>\n

The investigation focuses on the accuracy of Acadia\u2019s disclosures concerning its supplemental new drug application (\u201csNDA\u201d) for NUPLAZID\u00ae (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (\u201cDRP\u201d).<\/p>\n

On Jul. 20, 2020, Acadia announced the U.S. FDA accepted for filing the sNDA. The company also reassured investors \u201c[t]he FDA has also informed the company that it has not identified any potential review issues at this point in their evaluation and at this time they are not planning to hold an Advisory Committee meeting.\u201d<\/p>\n

But on Mar. 8, 2021, Acadia shocked its shareholders when it announced that on Mar. 3, 2021 the FDA informed the company that during review of the sNDA the agency identified deficiencies that preclude discussion of labeling and post-marketing requirements\/commitments at this time.\u00a0\u00a0<\/p>\n

Analysts were stunned by this news. RBC Capital Markets analyst Gregory Renza reportedly said that after receiving the notice on Mar. 3 and \u201ca subsequent five days of ghosting,\u201d he now expects the FDA to issue a Complete Response Letter rejecting Acadia\u2019s application.<\/p>\n

In response to these disclosures, Acadia\u2019s share price fell $20.76, or 45%, in a single trading day, on unusually heavy trading volume.<\/p>\n

\u201cWe\u2019re focused on investors\u2019 losses and whether Acadia may have misled investors by concealing FDA-related review risks for the sNDA,\u201d said Reed Kathrein, the Hagens Berman partner leading the investigation.<\/p>\n

If you are an Acadia investor and have significant losses, or have knowledge that may assist the firm\u2019s investigation, click here to discuss your legal rights with Hagens Berman<\/a>.<\/p>\n

\n Whistleblowers: <\/strong>Persons with non-public information regarding Acadia should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895<\/strong> or email ACAD@hbsslaw.com<\/a>.<\/p>\n

\n
\n About Hagens Berman<\/u>
\n <\/a>
\n
Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation.\u00a0\u00a0 More about the firm and its successes is located at hbsslaw.com<\/a>. For the latest news visit our newsroom<\/u><\/a> or follow us on Twitter at @classactionlaw<\/u><\/a>.<\/p>\n

\n Contact: <\/u>
\n
Reed Kathrein, 844-916-0895<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO, March 24, 2021 (GLOBE NEWSWIRE) — Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit: www.hbsslaw.com\/investor-fraud\/ACAD Contact An Attorney Now: ACAD@hbsslaw.com \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 844-916-0895 Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Investigation: The investigation focuses on the accuracy of Acadia\u2019s disclosures concerning its supplemental new drug application (\u201csNDA\u201d) for NUPLAZID\u00ae (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (\u201cDRP\u201d). On Jul. 20, 2020, Acadia announced the U.S. FDA accepted for filing the sNDA. The company also reassured investors \u201c[t]he FDA has also informed the company that it has not identified any potential review … <\/p>\n

Continue reading “HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-464500","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, March 24, 2021 (GLOBE NEWSWIRE) — Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit: www.hbsslaw.com\/investor-fraud\/ACAD Contact An Attorney Now: ACAD@hbsslaw.com \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 844-916-0895 Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Investigation: The investigation focuses on the accuracy of Acadia\u2019s disclosures concerning its supplemental new drug application (\u201csNDA\u201d) for NUPLAZID\u00ae (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (\u201cDRP\u201d). On Jul. 20, 2020, Acadia announced the U.S. FDA accepted for filing the sNDA. The company also reassured investors \u201c[t]he FDA has also informed the company that it has not identified any potential review … Continue reading "HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-24T18:37:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTkxMCM0MDkwMzE5IzIwMTg1MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys\",\"datePublished\":\"2021-03-24T18:37:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\\\/\"},\"wordCount\":460,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTkxMCM0MDkwMzE5IzIwMTg1MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\\\/\",\"name\":\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTkxMCM0MDkwMzE5IzIwMTg1MzI=\",\"datePublished\":\"2021-03-24T18:37:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTkxMCM0MDkwMzE5IzIwMTg1MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTkxMCM0MDkwMzE5IzIwMTg1MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/","og_locale":"en_US","og_type":"article","og_title":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys - Market Newsdesk","og_description":"SAN FRANCISCO, March 24, 2021 (GLOBE NEWSWIRE) — Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit: www.hbsslaw.com\/investor-fraud\/ACAD Contact An Attorney Now: ACAD@hbsslaw.com \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 844-916-0895 Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Investigation: The investigation focuses on the accuracy of Acadia\u2019s disclosures concerning its supplemental new drug application (\u201csNDA\u201d) for NUPLAZID\u00ae (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (\u201cDRP\u201d). On Jul. 20, 2020, Acadia announced the U.S. FDA accepted for filing the sNDA. The company also reassured investors \u201c[t]he FDA has also informed the company that it has not identified any potential review … Continue reading \"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-24T18:37:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTkxMCM0MDkwMzE5IzIwMTg1MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys","datePublished":"2021-03-24T18:37:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/"},"wordCount":460,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTkxMCM0MDkwMzE5IzIwMTg1MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/","name":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTkxMCM0MDkwMzE5IzIwMTg1MzI=","datePublished":"2021-03-24T18:37:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTkxMCM0MDkwMzE5IzIwMTg1MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTkxMCM0MDkwMzE5IzIwMTg1MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-investigating-acadia-pharmaceuticals-acad-for-possible-securities-law-violations-encourages-investors-with-losses-to-contact-its-attorneys-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=464500"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464500\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=464500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=464500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=464500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}